Sarcopenia Treatment Market Forecast Report 2024-2033: Key Trends and Strategies for Expansion

"The new report published by The Business Research Company, titled "" Sarcopenia Treatment Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the sarcopenia treatment market size has grown strongly in recent years. It will grow from $3.30 billion in 2023 to $3.52 billion in 2024 at a compound annual growth rate (CAGR) of 6.6%. The sarcopenia treatment market size is expected to see strong growth in the next few years. It will grow to $4.44 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=13926&type=smp

Surge In Malnutrition Boosts Sarcopenia Treatment Market Growth
The rise in malnutrition is expected to propel the growth of the sarcopenia treatment market going forward. Malnutrition refers to deficiencies, excesses, or imbalances in a person's intake of energy and nutrients, covering both undernutrition and overweight, obesity, and diet-related noncommunicable diseases. Sarcopenia treatment helps address the coexisting conditions of malnutrition and sarcopenia in older adults through interventions such as nutritional therapy and exercise, aiming to improve muscle mass, strength, and overall nutritional status. For instance, in December 2023, according to a report published by the World Health Organization (WHO), a Switzerland-based United Nations (UN) organization, malnutrition remains a significant global health challenge, with an estimated 462 million underweight and 149 million children under 5 suffering from stunting in 2022. Therefore, the rise in malnutrition is driving the growth of the sarcopenia treatment market.

Biophytis Receives FDA Authorization For Groundbreaking SARA-31 Phase 3 Study
Major companies operating in the sarcopenia treatment market are increasing their focus on development of multiple advance clinical option study to adhere with better treatment option. A clinical study is a systematic investigation conducted on human subjects to evaluate the safety, efficacy, and/or outcomes of a medical intervention. For instance, in September 2023, Biophytis, a France-based biotechnology company, announced the Food and Drug Administration (FDA) authorization to initiate the SARA-31 Phase 3 study in sarcopenia. The study aims to evaluate the efficacy and safety of Sarconeos (BIO101) in the treatment of sarcopenic patients at risk of motor disability. This study demonstrates a significant advancement in technological and pharmaceutical treatment approaches, offering potential efficacy and safety benefits for severe sarcopenic patients. It is the first-ever phase 3 study in sarcopenia and has received FDA authorization. The study will include around 900 patients aged over 65 with sarcopenia, low walking speed, and low hand grip strength. The primary endpoint will be the assessment of the risk of major mobility disability (MMD), walking speed, hand grip strength, and patient-reported quality of life.

The sarcopenia treatment market covered in this report is segmented -

1) By Treatment Type: Protein Supplements, Vitamin B12 Supplements, Vitamin D And Calcium Supplements, Other Treatment Types
2) By Type: Primary Sarcopenia, Secondary Sarcopenia
3) By Route Of Administration: Oral, Parenteral, Enteral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=13926&type=discount

Major companies operating in the sarcopenia treatment market report are Pfizer Inc., F-Hoffmann La-Roche, Merck Sharp & Dohme Corp. (Merck & Co.), AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Abbott Laboratories Inc., GlaxoSmithKline plc, Eli Lilly and Company, BASF SE, Nestle Health Science, Haleon Group of Companies, Regeneron Pharmaceuticals Inc., DSM, American Way (Amway) Corporation, Perrigo Company PLC, Intas Pharmaceuticals Ltd, Zydus Lifesciences, Fermenta Biotech Limited, Metagenics LLC, Ion Labs Inc., Makers Nutrition LLC, NutraScience Labs, AstaReal AB, NutraPak USA, BioThrive Sciences, Wellona Pharma, Healing Pharma India Pvt. Ltd., Nutrafill

Contents of the report:
1. Executive Summary
2. Sarcopenia Treatment Market Report Structure
3. Sarcopenia Treatment Market Trends And Strategies
4. Sarcopenia Treatment Market - Macro Economic Scenario
5. Sarcopenia Treatment Market Size And Growth
…..
27. Sarcopenia Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/sarcopenia-treatment-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

"Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide."

This release was published on openPR.